237 InnovaTV 301/ENGOT-Cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L Or 3L recurrent or metastatic cervical cancer

التفاصيل البيبلوغرافية
العنوان: 237 InnovaTV 301/ENGOT-Cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L Or 3L recurrent or metastatic cervical cancer
المؤلفون: Martín, Antonio Gonzalez, Slomovitz, Brian M, Fujiwara, Keiichi, Kalbacher, Elsa, Bagameri, Andrea, Ghamande, Sharad, Lee, Jung-Yun, Banerjee, Susana, Maluf, Fernando, Lorusso, Domenica, Yonemori, Kan, Nieuwenhuysen, Els Van, Sánchez, Luis Manso, Woelber, Linn, Westermann, Anneke, Covens, Allan, Whalley, Elizabeth, Leng Teng, Melinda Siew, Soumaoro, Ibrahima, Vergote, Ignace
المصدر: Oral Sessions
بيانات النشر: BMJ Publishing Group Ltd
سنة النشر: 2024
نوع الوثيقة: conference object
اللغة: unknown
DOI: 10.1136/ijgc-2024-esgo.7
DOI: 10.1136/ijgc-2024-ESGO.7
الإتاحة: https://doi.org/10.1136/ijgc-2024-esgo.7Test
رقم الانضمام: edsbas.9C9C4259
قاعدة البيانات: BASE